Notice Number: NOT-CA-20-056
Key Dates
Release Date: April 28, 2020
RFA-CA-19-045
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to update applicants about a change of the second receipt date for RFA-CA-19-045, "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)".
This new receipt date (October 30, 2020) will allow applicants more time to prepare for applications given the delays and complications caused by the COVID-19 pandemic.
The following sections of the FOA are being modified:
Part 1. Overview Information, Key Dates
Currently reads
Application Due Dates(s): October 30, 2019; July 30, 2020
Modified to read (in italics)
Application Due Dates(s): October 30, 2019; October 30, 2020
Currently reads
Scientific Merit Review: January 2020; September 2020
Modified to read (in italics)
Scientific Merit Review: January 2020; January 2021
Currently reads
Advisory Council Review: May 2020; January 2021
Modified to read (in italics)
Advisory Council Review: May 2020; May 2021
Currently reads
Earliest Start Date: July 2020; April 2021
Modified to read (in italics)
Earliest Start Date: July 2020; July 2021
Currently reads
Expiration Date: July 31, 2020
Modified to read (in italics)
Expiration Date: October 31, 2020
All other aspects of RFA-CA-19-045 remain unchanged.
Inquiries
Please direct all inquiries to:
Leah E. Mechanic, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-6847
Email: [email protected]
and Human Services (HHS)
